Article
The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.
Exploring the Effects of Masks on Skin Physiology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Which Tax Treatment Is Best for Your Dermatology Practice?
Facing Challenges in Pediatric Plaque Psoriasis